Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


1 Blood
2 Cancer Chemother Pharmacol
1 Exp Hematol
1 Int J Hematol
2 J Clin Oncol
2 Leuk Lymphoma
3 Leukemia

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. CHIBA M, Shimono J, Ishio T, Takei N, et al
    Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.
    Blood. 2022;140:1951-1963.
    PubMed         Abstract available

    Cancer Chemother Pharmacol

  2. JAISWAL A, Jaiswal A, Williamson EA, Gelfond J, et al
    Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis.
    Cancer Chemother Pharmacol. 2022 Nov 8. pii: 10.1007/s00280-022-04490.
    PubMed         Abstract available

  3. JOHNSON S, Dhamne C, Sankaran H, Gandhi KA, et al
    A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL).
    Cancer Chemother Pharmacol. 2022;90:445-453.
    PubMed         Abstract available

    Exp Hematol

  4. GAO X, You X, Droin N, Banaszak LG, et al
    Role of ASXL1 in hematopoiesis and myeloid diseases.
    Exp Hematol. 2022;115:14-19.
    PubMed         Abstract available

    Int J Hematol

  5. YANADA M, Yamasaki S, Konuma T, Mizuno S, et al
    Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.
    Int J Hematol. 2022 Nov 6. pii: 10.1007/s12185-022-03486.
    PubMed         Abstract available

    J Clin Oncol

  6. WANG T, Tang Y, Cai J, Wan X, et al
    Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.
    J Clin Oncol. 2022 Nov 8:JCO2201214. doi: 10.1200/JCO.22.01214.
    PubMed         Abstract available

  7. CASEY M, Odhiambo L, Aggarwal N, Shoukier M, et al
    Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?
    J Clin Oncol. 2022;40:3719-3729.
    PubMed         Abstract available

    Leuk Lymphoma

  8. FENG X, Zheng Y, Xu J
    Morphology and clinical characteristics of a case of FIP1L1-RARA fusion-associated variant acute promyelocytic leukemia.
    Leuk Lymphoma. 2022 Nov 9:1-4. doi: 10.1080/10428194.2022.2142052.

  9. CHEN WONGWORAWAT Y, Eskandari G, Gaikwad A, Marcogliese AN, et al
    Frequent detection of CBFA2T3::GLIS2 fusion and RAM-phenotype in pediatric non-Down syndrome acute megakaryoblastic leukemia: a possible novel relationship with aberrant cytoplasmic CD3 expression.
    Leuk Lymphoma. 2022 Nov 8:1-6. doi: 10.1080/10428194.2022.2140285.


  10. KOSCHADE SE, Klann K, Shaid S, Vick B, et al
    Correction: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia.
    Leukemia. 2022 Nov 8. pii: 10.1038/s41375-022-01721.

  11. MULLER J, Walter W, Haferlach C, Muller H, et al
    How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing.
    Leukemia. 2022 Nov 5. pii: 10.1038/s41375-022-01743.

  12. ADAMO A, Chin P, Keane P, Assi SA, et al
    Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.
    Leukemia. 2022 Nov 4. pii: 10.1038/s41375-022-01744.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.